Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial-Reference-Cited by-同舟云学术

Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial

Published:2022-01-12 Issue:2 Volume:42 Page:163-175
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Braal C. Louwrens^ORCID,Kleijburg Anne,Jager Agnes,Koolen Stijn L. W.,Mathijssen Ron H. J.,Corro Ramos Isaac,Wetzelaer Pim,Uyl-de Groot Carin A.

Funder

Erasmus Medisch Centrum

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-021-01114-6.pdf

Reference46 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0.

2. Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJAR, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expert Rev Clin Pharmacol. 2019;12(6):523–36. https://doi.org/10.1080/17512433.2019.1610390.

3. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019;37(5):423–38. https://doi.org/10.1200/JCO.18.01160.

4. Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019;37(33):3152–65. https://doi.org/10.1200/JCO.19.01472.

5. Antunes MV, Linden R, Santos TV, et al. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a Southern Brazilian population under tamoxifen pharmacotherapy. Ther Drug Monit. 2012;34(4):422–31. https://doi.org/10.1097/FTD.0b013e318260b46e.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer;PharmacoEconomics;2023-05-28

2. Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?;Breast Cancer: Targets and Therapy;2023-02

3. Cost-effectiveness of Tamoxifen versus Anastrozole in post-menopausal women with breast cancer: Saudi Arabia perspective;Journal of Medicine and Health Studies;2022-12-30